Safety and efficacy of Ahmed glaucoma valve implantation in refractory glaucomas in Northern Indian eyes

Dubey, Suneeta; Sharma, Vijeta; Agrawal, Anugya; Chauhan, Lokesh; Douglas, Gordon R.

doi:10.1016/j.sjopt.2014.06.007

Cited by 8 publications

(4 citation statements)

References 35 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Almost all types of glaucoma may evolve to refractory glaucoma, and the state of the conjunctiva together with a patient’s systemic health state may precipitate this condition. For these reasons, glaucoma filtration devices such as the Ahmed Glaucoma Valve (New World Medical, Rancho Cucamonga, CA, USA), Baerveldt (Advanced Medical Optics, Inc., Santa Ana, CA, USA), or Molteno (IOP, Inc., Costa Mesa, CA, USA, and Molteno Ophthalmic Limited, Dunedin, New Zealand) valves have been demonstrated to be safe and effective in lowering IOP and are therefore widely used in complex cases such as secondary and refractory glaucoma [ 4 , 5 , 6 , 7 , 8 , 9 ].…”

Section: Introductionmentioning

confidence: 99%

“…It reduces to 49% at five years after surgery, with a 10% per year failure rate [ 3 , 8 ]. Dubey and co-authors reported a success rate in Northern Indian eyes with refractory glaucoma of 85.45% at one year and 79.63% at three years after AGV implantation [ 9 ]. In the case of AGV implant failure, the possible subsequent options are the revision of the first AGV (tube repositioning and capsule revision), a second AGV implant, or cyclodestructive procedures.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Safety and Efficacy of Second Ahmed Valve Implant in Refractory Glaucoma

Posarelli

Toro

Ręjdak

et al. 2020

JCM

View full text Add to dashboard Cite

Background: Refractory glaucoma still represents a challenge for ophthalmologists to manage intraocular pressure. The present study aimed to evaluate long term efficacy and safety of a second Ahmed valve implantation after the failure of a first implant in patients with refractory glaucoma and elevated intraocular pressure (IOP). Methods: Retrospective, multicenter non-comparative case series. Twenty-eight patients were retrospectively recruited between January 2011 and December 2017. Demographic data, glaucoma type, visual acuity, intraocular pressure, medical therapy, and complications were registered. Three criteria of success were established: Type 1 surgical success: IOP ≤ 15 mmHg and a reduction of IOP ≥ 40% from baseline; Type 2 surgical success: IOP ≤ 18 mmHg and a reduction of IOP ≥ 30% from baseline; and Type 3 surgical success: IOP ≤ 21 mmHg and a reduction of IOP ≥ 20% from baseline. Surgical failure has been established as IOP less than 5 mmHg or over 21 mmHg and less than a 20% reduction of IOP from baseline despite medications in two consecutive visits, light perception loss referable to glaucoma, and the necessity for further glaucoma surgery. Failure was observed in six (21%) patients. (3) Results: Mean IOP and mean glaucoma medication number significantly reduced from baseline after the second implantation, and the surgical success rate at 72 months ranged from 10% to 78% based on the different criteria of success. Failure was observed in six (21%) patients. Conclusions: This study confirmed the safety and efficacy of a second Ahmed valve implantation in patients with refractory glaucoma and elevated IOP at baseline.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Safety and Efficacy of Second Ahmed Valve Implant in Refractory Glaucoma

Posarelli

Toro

Ręjdak

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…[ 9 , 10 ] Hence, AGV implantation was planned in OD to reduce IOP, as they have a good long term success rate of 70%–90% at 2 years follow-up with very low incidence of endophthalmitis. [ 11 ]…”

Section: Discussionmentioning

confidence: 99%

Glaucoma drainage device implantation in a pregnant woman with axenfeld–rieger syndrome

Ramesh,

Krishnadas,

Senthilkumar

et al. 2023

Oman J Ophthalmol

View full text Add to dashboard Cite

Axenfeld–Rieger syndrome (ARS) is a rare disease characterized by anterior segment anomalies with or without glaucoma. A 28-year-old antenatal female diagnosed with ARS presented with uncontrolled intraocular pressures (IOPs) and advanced glaucoma despite maximal medical therapy and progressive vision loss during her third trimester. The refractory and progressive nature of the disease, with useful vision in one eye, necessitated immediate surgical intervention, following which there was successful control of IOP, lasting till the final follow-up at 18 months. We discuss the role of glaucoma surgery, for an ARS patient with refractory glaucoma during the third trimester with a comprehensive review of literature.

show abstract

“…AGV implantation was performed in patients with secondary glaucoma who had superior conjunctival scarring as per standardized technique. [ 7 ] Glaucoma surgeries were performed by three experienced surgeons. Post-operatively, patients received Moxifloxacin 0.5% four times a day and Pred Forte 1% eight times a day for one week.…”

Section: Methodsmentioning

confidence: 99%

Consensual eye intra-ocular pressure rise following unilateral glaucoma surgery

Rajsrinivas

Dubey

Pegu

et al. 2023

Indian Journal of Ophthalmology

Self Cite

View full text Add to dashboard Cite

Purpose: Consensual eye intra-ocular pressure (IOP) increase has been reported following ipsilateral glaucoma surgery. The study evaluated the need for increase in anti-glaucoma medications (AGM) ± glaucoma surgery to control the IOP in consensual eye following unilateral glaucoma surgery. Methods: Data of 187 consecutive patients who underwent either trabeculectomy or AGV implant were collected. Index (IE) and fellow eye (FE) IOP (baseline, follow-up day 1, week 1, months 1 and 3), acetazolamide and AGM use, FE surgery, glaucoma status, and relevant ophthalmological data were collected. Results: A significant increase from a baseline IOP of 14.4 mmHg was noted at week 1 (15.8 mmHg, p-0.005) and month 1 (15.62 mmHg, p-0.007) in FE (n-187). Among the 61 patients (33%, n-187) who needed additional intervention to reduce FE IOP, 27 (14.4%) underwent FE trabeculectomy. In the IE trabeculectomy group (n-164), significant increase in FE IOP was noted in week 1 (15.87 mmHg, p-0.014) and month 1 (15.61 mmHg, p-0.02), and in the IE AGV group (n-23) at day 1 (15.91 mmHg, p-0.06). Pre-operative acetazolamide resulted in significant increase in FE IOP at week 1 and month 1. Maximum increase in FE IOP of nearly 3.5 mm Hg was noted when IE IOP was persistently <5 mmHg at one month following surgery. Mean FE IOP remained elevated at all visits. Conclusion: An increase in fellow eye IOP needing any additional intervention in a third and surgical intervention in nearly a sixth meant that FE IOP be strictly monitored and addressed following unilateral glaucoma surgery.

show abstract

Safety and efficacy of Ahmed glaucoma valve implantation in refractory glaucomas in Northern Indian eyes

Abstract: AGV implantation has proven to be safe and is effective in controlling IOP in refractory glaucoma in Northern Indian eyes.

Cited by 8 publications

References 35 publications

Safety and Efficacy of Second Ahmed Valve Implant in Refractory Glaucoma

Safety and Efficacy of Second Ahmed Valve Implant in Refractory Glaucoma

Glaucoma drainage device implantation in a pregnant woman with axenfeld–rieger syndrome

Consensual eye intra-ocular pressure rise following unilateral glaucoma surgery

Contact Info

Product

Resources

About